Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

peginterferon alfa-2b

(peg-IN-ter-FEER-on AL-fuh ...)

A drug that is no longer available in the United States that was used under the brand name Sylatron to prevent melanoma from coming back after it has been removed by surgery and under the brand name PEG-Intron to treat chronic hepatitis C. Peginterferon alfa-2b is a form of interferon alfa (a substance normally made by cells in the immune system) that is made in the laboratory and linked to a substance called PEG, which makes the drug stay in the body longer. It is a type of cytokine and a type of immunomodulating agent.

peginterferon alfa-2b

Search NCI's Dictionary of Cancer Terms